In contrast, similar serum FSCN1 determinations, performed in patients diagnosed with lung cancer, laryngeal carcinoma and hepatocellular carcinoma, were correlated to tumor aggressiveness [32,38,49]. This evidence concerns the gene FSCN1 and hepatocellular carcinoma.